Eli Lilly and Co News - LLY

Professional-Grade Tools, for Individual Investors.

Premium

Form 3 - Initial statement of beneficial ownership of securities

Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference

Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference PR Newswire INDIANAPOLIS, June...

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities

Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting

Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in...

Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions

Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions PR...

Eli Lilly Expands Pain Treatment Pipeline with SiteOne Therapeutics Acquisition

Eli Lilly and Company (NYSE: LLY) is advancing its neuroscience portfolio by acquiring SiteOne Therapeutics in a deal valued at up to $1 billion...

Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics

Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics PR Newswire INDIANAPOLIS, May 27...

Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual...

Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease

Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early...

Form 144 - Report of proposed sale of securities

Novo Nordisk Inks $2.2 Billion Deal with Septerna to Advance Obesity and Diabetes Treatments

Novo Nordisk (NYSE: NVO) has entered into a collaboration and licensing agreement with U.S.-based biotech firm Septerna (NASDAQ: SEPN) to...

Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine

Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results...

Form SD - Specialized disclosure report

Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation

Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate...

Form 8-K - Current report

BottomBounce 3 weeks ago

First, @P_McCulloughMD who is one of the most published people in the world on Covid vaccine myocarditis spoke.

He saw warning signs as early as August of 2021 that the vaccines can cause myocarditis… pic.twitter.com/Gexd9yXOhU— Anna Matson (@AnnaRMatson) May 22, 2025 $LLY

👍️0

BottomBounce 1 month ago

$LLY "This is not a vaccine... It's a genetic experiment at best. And that's without even talking about all the nanotech, just... the biological elements...this is Frankenstein science... [and before COVID] less than 400 humans were ever experimented with with MRNA."

Dr. Mark Trozzi… pic.twitter.com/eBB4NOa3I8— Sense Receptor (@SenseReceptor) May 14, 2025 LLY

👍️0

TechandBio 1 month ago

GSK pays 2 Billion for Boston Pharma a IV LLY should scoop up SGMT the oral with the breakthrough designation.

MDGL just partnered with SGMT combining one oral tablet makes MDGL THR Beta work 80% compared to 25% alone Plus works incredibly well with GLP1 data with semaglutide & SGMT oral enhanced efficacy tremendously with SGMT Fatty synthesis the only one in the clinic world wide. SGMT has breakthrough designation for their phase 3 ready Mash Trials and Pediatric Mash the only in the clinic phase 2 Ready for Pediatric

$LLY

👍️0

Saving Grace 1 month ago

The pump before the dump! Look out below. Super cave Tuesday coming.

👍️0

BottomBounce 1 month ago

So many children are getting cancer, yet, no one wants to consider vaccines as the culprit.

This needs to change. @RobertKennedyJr @POTUS pic.twitter.com/ZvK4IgS2T5— Died Suddenly (@DiedSuddenly_) May 10, 2025 $LLY

👍️0

BottomBounce 1 month ago

$LLY Total Debt (mrq) $34.91B

👍️0

Monksdream 2 months ago

LLY, 10Q due 5/1

👍️0

makinezmoney 2 months ago

$LLY: Those 4/17 $800calls ..... PURE GENIUS.... up 535,900%

JUST ON THE DAY !!!!!!!!!!!!!

You wanna hit the LOTTERY on the OPTIONS MARKET................ THATs HOW YOU EFFIN DO !!!!!!!!!

This has to be the biggest INTRADAY Options YIELD I have EVER SEEN.

I don't think the days of seeing a 1Million% yield are far off now............ That is going to make someone AN INSTANT BILLIONAIRE !!!!!

I can't believe more people aren't talking about this here.

Completely MIND BLOWING.... everyone out there pumping their PENNY STOCKS while this is how you make that EZ MONEY baby.

These wkly $800 calls were only $0.01 yesterday............. right now they are at $53.60 !!!!!!!!!!!!

0dte calls are HYPERACTIVE MONEY MAKERS if you know you're crap and there were clearly some loaders on this YESTERDAY as you can see the volume activity on this chart.

This news came out at 6am EST today but you can see from yesterdays activity, there
were insiders and their friends that were clearly ahead of the game and were already positioning
themselves in on these.

https://www.prnewswire.com/news-releases/lillys-oral-glp-1-orforglipron-demonstrated-statistically-significant-efficacy-results-and-a-safety-profile-consistent-with-injectable-glp-1-medicines-in-successful-phase-3-trial-302430985.html

GO $LLY

👍 2

double_m 2 months ago

And who says buying the dip was a bad idea. I love this stock!!! 🚀

👍️0

makinezmoney 2 months ago

$LLY: Amazing 560k % YIELD on those $800wkly calls !!!!!!!!!!!!!!

GO $LLY

👍️0

BottomBounce 2 months ago

$LLY Total Debt (mrq) $34.91B Pump and Dump Scam stock https://www.cnbc.com/2025/03/31/vaccine-stocks-fall-after-fdas-peter-marks-resigns-over-rfk-jr.html

👍️0

TechandBio 3 months ago

Back in option play up 24% in a week for July

$LLY

👍️0

BottomBounce 5 months ago

Eli Lilly and Company $LLY Total Debt (mrq) $31.23B Massive debt compared to dwinding cash. Pump and dump

👍️0

peanutz 5 months ago

Another gloom and doomer . Lilly is fine . I worked there over 10 years and they have a ton in the pipeline . It needs a breather . Crash my a$$

👍️0

MartinLutherKing 5 months ago

RNAZ micro rna cancer cure ELAB el-22 obesity target buyout in progress

👍️ 1

MomsSpaghetti 6 months ago

Are you saying small biotech has a chance...? I was thinking the other way...

Eli Lilly has been a major player in CNS disorders, particularly with treatments for depression (e.g., Prozac) and schizophrenia. They are actively exploring new areas in psychiatry, including the potential for psychedelics.

Lilly has shown interest in novel treatments for depression and anxiety and has partnered with companies in the psychedelic space. Their expansion into the psychedelic field could be an opportunity to leverage MindMed's expertise in developing treatments using substances like LSD and MDMA.

I am wondering if they (or others) would might possibly acquire them.

👍️0

fung_derf 7 months ago

I've been waiting and waiting for this one to pull back and it has. However, it is fighting mightily to hold support here....Right now I'm thinking it looks moderately hopeful here, but I think $NVO has become the better play now.

👍️0

Saving Grace 7 months ago

Industry changing direction. Big Pharma going south! LLY a major short candidate going into 2025.

👍️0

TechandBio 8 months ago

$1000 strikes for Jan 2025 look juicy.

$LLY

👍️0

uksausage 8 months ago

why?

👍️0

Saving Grace 8 months ago

Big Pharma to crash hard. Be prepared!

👍️0

TechandBio 9 months ago

Wonder if Lily Buys SMMT.
$LLY

👍️0

DewDiligence 10 months ago

LLY offers Zepbound in_single-use_vials_at_sharply_reduced_prices—(yesterday’s news):

https://www.nytimes.com/2024/08/27/well/eli-lilly-zepbound-price.html On Tuesday, Eli Lilly announced that it would start selling low doses of its weight-loss drug Zepbound in vials… — at a far lower price than its pens, which come with pre-filled doses. These vials will be made available only through LillyDirect, a telehealth platform the company launched in January (https://investor.lilly.com/news-releases/news-release-details/lilly-launches-end-end-digital-healthcare-experience-through ).

…The vials are significantly cheaper than Zepbound pens, which cost just over $1,000 a month without insurance. A month’s supply of the 2.5-milligram dose will cost $399, and a month’s worth of the five-milligram dose will cost $549.

… The company will offer vials with only the two lowest doses of Zepbound. Many patients stay on a five milligram dose… but some gradually increase their dose, up to a maximum of 15 milligrams. Any patient interested in taking more than the five-milligram dose would have to transition to the pens.

…the move could help Lilly regain customers who are currently getting compounded tirzepatide, which typically costs between roughly $250 and $450 a month. Why would anyone want a compounded formulation of tirzepatide derived from Chinese API when they can get the real thing from LLY at close to the same price?

👍️0

Monksdream 10 months ago

LLY new 52=week high

👍️0

EnchantedTitan62 10 months ago

To quote Areosmith ' I'm back in the saddle again' . 💰

👍️0

EnchantedTitan62 10 months ago

In the green premarket again. 🍷

👍️0

EnchantedTitan62 10 months ago

Bought back in at open today. 🍷

👍️0

EnchantedTitan62 10 months ago

In regards to new a pharma product.

👍️0

Zardiw 10 months ago

$LLY Chart from #DDAmanda - #1 Stock Screener :

Z

👍️0

EnchantedTitan62 10 months ago

Just sold my LLY shares. Wonderful way to ease into the weekend. Good luck to everyone today.

👍️0

EnchantedTitan62 10 months ago

Added @ $866.29

👍️0

EnchantedTitan62 10 months ago

Going to be another green day.

👍️0

EnchantedTitan62 10 months ago

I don't think they have sales in Europe yet, that'll change. 💰💰💰

👍️0

EnchantedTitan62 10 months ago

Uh, probably not .

👍️0

Monksdream 11 months ago

LLY new 52=week high

👍️0

EL Sueno 11 months ago

Let's go fans 1000.00!!!

👍️0

Monksdream 12 months ago

LLY new 52 week high

👍️0

Monksdream 12 months ago

LLY new 52 week high

👍️0

Monksdream 1 year ago

LLY 10Q due 4/30
Next day setttlement begins 5/28

👍️0

north40000 1 year ago

FDA advises LLY it wants AdCom meeting. Portends delay. Meanwhile NVO CEO was interviewed on CNBC-TV this morning, repeats NVO’s PR warning dated in January 2024 that it will not have manufacturing capacity to fill demand for its weight loss drug until 2006(?).

👍️0

Alfonz66 1 year ago

Sell now boys you had a great run

👍️0

Monksdream 1 year ago

LLY new 52 week high

👍️0

Monksdream 1 year ago

LLY new 52 week high

👍️0

oldstocks 1 year ago

Eli Lilly was investigating Talampanel prior to 2010

For the treatment of epilepsy, malignant gliomas and ALS
development codes LY-300164 , LY300164
results from the trial for ALS have been found negative
Talampanel is not currently under development.
It showed effectiveness for epilepsy in clinical trials but its development was suspended due to its poor pharmacokinetic profile, namely a short terminal half-life (3 hours) that necessitated multiple doses per day.
RespireRx Pharmaceuticals $ RSPI a little unknown company KRM–II–81 has shown promising results for Epilepsy.
Has fully suppressed the epileptiform activity in the excised brain tissue from a 19-year-old patient with pharmaco-resistant epilepsy.

👍️0

ralphey 1 year ago

I bought Lilly about a year ago based on Mounjaro and knowing it was going to be a success. I am a FAmily Doc who has done bariatric medicine for 30 years. Zepbound definitely is inducing more weight loss than Ozempic (Wegovy) but I am getting concerned over the number of patients that are stopping zepbound / Mounjaro due to side effects, seems a lot more than on Ozempic ( Wegovy) .

👍️0

Monksdream 1 year ago

Incredible, isn’t it
What gets me about these social media bozos is they actually believe they will become Boca Raton rich by day trading sub $1 stocks
Because they are incapable of researching companies

Monksdream 1 year ago

LLY new 52=week high

👍️0

Monksdream 1 year ago

LLY new 52 week high

👍️0

Monksdream 1 year ago

LLY new 52 week high

👍️0

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Eli Lilly and Co (LLY)

Professional-Grade Tools, for Individual Investors.

LLY News

Form 3 - Initial statement of beneficial ownership of securities

Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities

Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting

Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions

Eli Lilly Expands Pain Treatment Pipeline with SiteOne Therapeutics Acquisition

Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics

Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease

Form 144 - Report of proposed sale of securities

Novo Nordisk Inks $2.2 Billion Deal with Septerna to Advance Obesity and Diabetes Treatments

Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine

Form SD - Specialized disclosure report

Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation

Form 8-K - Current report

LLY Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Eli Lilly and Co (LLY) News

Eli Lilly and Co (LLY)

Professional-Grade Tools, for Individual Investors.

LLY News

Form 3 - Initial statement of beneficial ownership of securities

Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference

Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities

Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting

Lilly announces details of presentations at American Diabetes Association's (ADA) 85th Scientific Sessions

Eli Lilly Expands Pain Treatment Pipeline with SiteOne Therapeutics Acquisition

Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics

Lilly announces details of presentations at 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Lilly's Kisunla (donanemab) receives marketing authorization in Australia for the treatment of early symptomatic Alzheimer's disease

Form 144 - Report of proposed sale of securities

Novo Nordisk Inks $2.2 Billion Deal with Septerna to Advance Obesity and Diabetes Treatments

Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine

Form SD - Specialized disclosure report

Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation

Form 8-K - Current report

LLY Discussion

Your Recent History

Go Ad-Free